TOPLINE:

In patients with type 2 diabetes (T2D), treatment with oral semaglutide demonstrated a modest but significant reduction in serum urate levels, with substantially greater reductions observed in those with baseline serum urate levels > 6 mg/dL. Those with baseline hyperuricemia and those switching from DPP-4 inhibitors were more likely to achieve a serum urate level of < 6 mg/dL.

METHODOLOGY:

Researchers conducted a retrospective real-world study to examine the effects of oral semaglutide treatment on serum urate levels in patients with T2D.

The analysis included 236 adults with T2D (median age, 64 years; 40.7% women) who initiated oral semaglutide treatment between November 2021 and November 2022 across 12 healthcare centers in Spain; 12.3% of patients were receiving urate-lowe

See Full Page